We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+41.65%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.17B
AUM Growth
+$2.33B
Cap. Flow
+$258M
Cap. Flow %
4.18%
Top 10 Hldgs %
45.67%
Holding
151
New
35
Increased
25
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$54.2M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$47.1M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$40.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.1M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$38.9M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$102M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$53.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.9M
4
TBPH icon
Theravance Biopharma
TBPH
+$23.1M
5
NVRO
NEVRO CORP.
NVRO
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.05%
2 Financials 0.28%
3 Materials 0.1%
4 Technology 0.1%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$380M 6.15%
25,182,364
– –
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$369M 5.98%
5,842,100
-223,626
-4% -$15.3M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.04B
$324M 5.25%
11,809,494
+139,437
+1% +$4.58M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$316M 5.13%
2,771,050
-548,400
-17% -$53.2M
NBIX icon
5
Neurocrine Biosciences
NBIX
$18.3B
$261M 4.23%
2,141,410
-921,853
-30% -$102M
BBIO icon
6
BridgeBio Pharma
BBIO
$16.6B
$219M 3.54%
6,706,268
– –
KOD icon
7
Kodiak Sciences
KOD
$2.44B
$190M 3.08%
3,513,572
-149,985
-4% -$8.46M
VBIV
8
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$171M 2.77%
1,834,749
+303,030
+20% +$16.7M
ATNX
9
DELISTED
Athenex, Inc. Common Stock
ATNX
$156M 2.53%
576,623
– –
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$148M 2.39%
3,514,358
+30,000
+0.9% +$1.07M
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$135M 2.18%
1,395,017
+80,808
+6% +$6.74M
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$133M 2.15%
4,907,139
+1,454,218
+42% +$40.1M
ZYME icon
13
Zymeworks
ZYME
$1.63B
$129M 2.09%
3,580,999
+20,000
+0.6% +$737K
NVRO
14
DELISTED
NEVRO CORP.
NVRO
$108M 1.74%
899,972
-192,096
-18% -$22.8M
QTNT
15
DELISTED
Quotient Limited Ordinary Shares
QTNT
$98.3M 1.59%
332,226
– –
MGTX icon
16
MeiraGTx Holdings
MGTX
$1.08B
$80.5M 1.31%
6,433,277
– –
KDMN
17
DELISTED
Kadmon Holdings, Inc.
KDMN
$80.4M 1.3%
15,711,334
– –
KRRO icon
18
Korro Bio
KRRO
$148M
$70.5M 1.14%
60,686
– –
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
$68.9M 1.12%
1,095,129
+420,000
+62% +$23.1M
ALLO icon
20
Allogene Therapeutics
ALLO
$583M
$66.1M 1.07%
1,543,790
– –
PRVB
21
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$63.9M 1.03%
4,525,711
+1,514,137
+50% +$19.1M
CRNX icon
22
Crinetics Pharmaceuticals
CRNX
$8.88B
$59.2M 0.96%
3,659,381
+1,071,428
+41% +$18.3M
FMTX
23
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$58.1M 0.94%
+1,250,000
New +$54.2M
VAPO
24
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$54.9M 0.89%
167,345
-41,413
-20% -$8.73M
BPMC
25
DELISTED
Blueprint Medicines
BPMC
$53.7M 0.87%
688,624
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Perceptive Advisors held 151 positions worth $6.17B, up 61% from $3.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors deployed $258M of net new capital in Q2 2020, opening 35 new positions and adding to 25 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 95% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $102M trimmed.

  • Perceptive Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.
  • Perceptive Advisors added most to Zogenix, Inc. in Q2 2020, an estimated $40.1M increase.
  • Perceptive Advisors's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $102M.
  • Perceptive Advisors fully exited Theravance Biopharma in Q2 2020, selling an estimated $23.1M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $6.17B portfolio in Q2 2020.
  • Perceptive Advisors opened 35 new positions and closed 26 in Q2 2020.
  • Perceptive Advisors's portfolio value rose 61% quarter-over-quarter to $6.17B.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.